Skip to Main Content

Mark Walters


Pediatric hematologist-oncologist
Bone marrow transplant specialist
Division Chief, Hematology, UCSF Benioff Children’s Hospitals
Audiobook listener, home cook and fan of comedians

Dr. Mark Walters is a hematologist-oncologist who cares for children with blood disorders and cancer, and specializes in blood and bone marrow transplants. He is director of the Pediatric Blood and Marrow Transplant Program at UCSF Benioff Children's Hospital Oakland.

Walters' research focuses on transplant and gene therapy for sickle cell disease and thalassemia – which are both red blood cell disorders that involve abnormalities of hemoglobin (the protein in red blood cells that carries oxygen). His goal is to offer a curative therapy to every child he treats. Because finding a healthy donor for sickle cell disease can be difficult, he also investigates methods that aim to correct the patient's own blood system through gene therapy and return the edited blood cells to the patient's circulation.

Walters earned his medical degree from the University of California, San Diego School of Medicine. He completed a residency in pediatrics at the University of Washington School of Medicine, followed by a fellowship in pediatric hematology-oncology at the Fred Hutchinson Cancer Research Center.

  • Education

    UC San Diego School of Medicine, MD, 1985

  • Residencies

    University of Washington, Pediatrics, 1988

  • Fellowships

    Fred Hutchinson Cancer Research Center, Pediatric Hematology-Oncology, 1991

I have the same mission as Benioff Children’s Hospital Oakland: to treat and improve the outcome for every child and family who comes here for care and support.

Where I see patients (3)

    Decorative Caduceus

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoi...

    The adverse event rate will be summarized using descriptive statistics, together with 95% confidence intervals where appropriate. No formal statistical hypothesis testing will be performed. Adverse events defined: failure of engra...


    More about this study
    Decorative Caduceus

    A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)

    Each patient will be classified as either a success or a failure (binary endpoint). Success is defined as a complete absence of severe VOEs (defining VOE as a painful event or ACS with no medically determined cause other than a va...


    More about this study
    See all clinical trials

    Saving future lives

    500+ UCSF investigators are researching cures for hundreds of childhood and adult diseases.